Stratification of Barrett’s esophagus surveillance based on p53 immunohistochemistry: a cost-effectiveness analysis by an international collaborative group
Endoscopy · 01.10.2024 · 56 (10) · 727-736
DOI: 10.1055/a-2317-8184 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.10.2024. Verfasst von Shyam Menon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom of Great Britain and Northern Ireland. Hauptthemen laut MEDLINE: Barrett Esophagus, Tumor Suppressor Protein p53, Cost-Benefit Analysis, Immunohistochemistry. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 76 Literaturangaben.
Abstract (Originalsprache)
Background
Surveillance of nondysplastic Barrett’s esophagus (NDBE) is recommended to identify progression to dysplasia; however, the most cost-effective strategy remains unclear. Mutation of TP53 or aberrant expression of p53 have been associated with the development of dysplasia in BE. We sought to determine if surveillance intervals for BE could be stratified based on p53 expression.
Methods
A Markov model was developed for NDBE. Patients with NDBE underwent p53 immunohistochemistry (IHC) and those with abnormal p53 expression underwent surveillance endoscopy at 1 year, while patients with normal p53 expression underwent surveillance in 3 years. Patients with dysplasia underwent endoscopic therapy and surveillance.
Results
On base-case analysis, the strategy of stratifying surveillance based on abnormal p53 IHC was cost-effective relative to conventional surveillance and a natural history model, with an incremental cost-effectiveness ratio (ICER) of $8258 for p53 IHC-based surveillance. Both the conventional and p53-stratified surveillance strategies dominated the natural history model. On probabilistic sensitivity analysis, the p53 IHC strategy ($28 652; 16.78 quality-adjusted life years [QALYs]) was more cost-effective than conventional surveillance ($25 679; 16.17 QALYs) with a net monetary benefit of $306 873 compared with conventional surveillance ($297 642), with an ICER
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gastroenterology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, United Kingdom of Great Britain and Northern Ireland.
- Health Economist, School of Population Health, Curtin University, Perth, Australia.
- Gastroenterology and Hepatology, Mayo Clinic, Rochester, United States.
- Curtin Medical School, Curtin University, Perth, Australia.
- Gastroenterology and Hepatology, Royal Perth Hospital, Perth, Australia.
ORCID-Profile: Shyam Menon
Zitieren
APA
Menon, S., Norman, R., Iyer, P. G., & Ragunath, K. (2024). Stratification of Barrett’s esophagus surveillance based on p53 immunohistochemistry: a cost-effectiveness analysis by an international collaborative group. Endoscopy, 56(10), 727-736. https://doi.org/10.1055/a-2317-8184
Vancouver
Menon S, Norman R, Iyer PG, Ragunath K. Stratification of Barrett’s esophagus surveillance based on p53 immunohistochemistry: a cost-effectiveness analysis by an international collaborative group. Endoscopy. 2024;56(10):727-736. doi:10.1055/a-2317-8184
BibTeX
@article{Menon2024,
author = {Menon, Shyam and Norman, Richard and Iyer, Prasad G and Ragunath, Krish},
title = {Stratification of Barrett’s esophagus surveillance based on p53 immunohistochemistry: a cost-effectiveness analysis by an international collaborative group},
journal = {Endoscopy},
year = {2024},
volume = {56},
number = {10},
pages = {727--736},
doi = {10.1055/a-2317-8184}
}
EUVIMED